Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

ISAL 2019 | Targeted therapy for AML: current outlook and future potential

Lars Bullinger • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Midostaurin

Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, talks to us about the current landscape and future role for targeted therapies in acute myeloid leukemia (AML).

More from Lars Bullinger

1:49
Bringing precision medicine and MRD into clinical strategies
Lars Bullinger • 15 Jun 2020
1:56
Minimal gene panel in AML
Lars Bullinger • 15 Jun 2020
2:09
EHA: AML immuno-oncology updates
Lars Bullinger • 15 Jun 2020
1:36
Innovations in MDS and AML treatment
Lars Bullinger • 15 Jun 2020

Related Videos

2:05
CAR T-cell therapy programs to improve access for patients with leukemia in Mexico
Alberto Olaya-Vargas • 15 Apr 2024
14:43
Current research into post-alloSCT maintenance therapy in AML
Ali Bazarbachi • 3 May 2024
5:20
Targeted therapies in AML: menin, FLT3 and IDH inhibitors
Felicitas Thol • 19 Apr 2024
4:15
Using MRD to guide post-alloSCT treatment decisions in AML
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals